$REVB News

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

REVB 2026 Starts in Positive Fashion

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate

Revelation Biosciences Files Prospectus For The Resale Of 4,272,500 Shares Via Warrants For Potential Proceeds Up To ~$14.7M

Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

REVB Comes to Agreement with FDA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

How Do Investors Really Feel About Revelation Biosciences Inc?

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

Revelation Biosciences shares are trading lower after the company announced a 1-for-4 reverse stock split.